ABIA marches for access to Sofosbuvir
August 25, 2018
ABIA, in partnership with the accessibsa project, protested pharma giant Gilead’s pursuit of patents on Sofosbuvir, a critical Hepatitis-C drug in Brazil. ABIA urged the Brazilian government to reject Gilead’s one remaining patent application for Sofosbuvir, a move which would allow the more affordable generic to be legally available in Brazil.
For more, see here.
Images and video from demonstrations in Rio de Janeiro and São Paulo: